BioAtla OKd to proceed with study for advanced adenocarcinoma candidate

 

• Following the IND clearance, the Company is advancing into a Phase 1 clinical study

• Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate

BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate BA3182 (CAB-EpCAMxCAB-CD3 bispecific T-cell engager) for the treatment of advanced adenocarcinoma. BioAtla plans to initiate and advance a Phase 1 dose-escalation and expansion clinical study in 2023.

https://finance.yahoo.com/news/bioatla-announces-fda-clearance-investigational-130000222.html